Overview
- Vlahos, C.J. et al. (1994) J. Biol. Chem. 269, 5241.
Alomone Labs LY 294002 inhibits AKT phosphorylation via PI3-kinase in NIH-3T3 cells.Cells were preincubated for 30 min in different concentrations of LY 294002 (#L-300) or Wortmannin (#W-400) and then stimulated with PDGF (3 ng/ml) for 20 min. Cell proteins were resolved by SDS-PAGE and probed with (A) anti-phospho-AKT antibody, followed by stripping and reprobed with (B) anti-Akt antibody.
- Kapeller, R. et al. (1994) Bioessays 16, 565.
- Duronio, V. et al. (1998) Cell Signal. 10, 233.
- Vlahos, C.J. et al. (1994) J. Biol. Chem. 269, 5241.
- Vlahos, C.J. et al. (1995) J. Immunol. 154, 2413.
- Curnock, A.P. et al. (1998) Cell. Immunol. 187, 77.
- Nicholson, K.M. et al. (2003) Cancer Lett. 190, 31.
- Coffer, P.J. et al. (1998) Biochem. J. 335 (Pt 1), 1.
- Shao, J. et al. (2004) Cancer Res. 64, 229.
- Vivanco, I. et al. (2002) Nat. Rev. Cancer 2, 489.
PI 3-kinase is an enzyme implicated in growth factor signal transduction by associating with receptor and non-receptor tyrosine kinases.1,2 LY-294002 is a potent and specific cell-permeable inhibitor of Pl 3-kinase that acts on the ATP-binding site of the enzyme.3
In in vitro assays it displays an IC50 of 1.4 µM on purified PI 3-kinase, but did not inhibit PKC, PKA, MAP kinase and PI 4-kinase.3 In fMet-Leu-Phe stimulated neutrophils, LY-294002 completely abolished PI 3-kinase activity at 50 µM.4 LY-294002 induces apoptosis in many cell types by blocking the PI3-K/Akt anti-apoptotic pathway.5,6 Thus LY-294002 is useful tool for identifying the biochemical events regulated by the PI3-K/Akt pathway.7 This pathway has important relevance to the cellular events involved in cancer.6,8,9
LY 294002 (#L-300) is a highly pure, synthetic, and biologically active compound.
Applications
Citations
Powered by Bioz- Puckett, M.C. et al. (2013) Mol. Cell. Biol. 33, 2252.
